We are live on
!
Find out more
FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
-9.64%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.17B
AUM Growth
–
Cap. Flow
+$1.17B
Cap. Flow
% of AUM
100.06%
Top 10 Holdings %
Top 10 Hldgs %
60.23%
Holding
42
New
42
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcutis Biotherapeutics
ARQT
|
+$143M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
+$94.1M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
+$72.8M |
| 4 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$67.2M |
| 5 |
IMGO
Imago BioSciences, Inc. Common stock
IMGO
|
+$61.6M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.72% |
| 2 | Miscellaneous | 1.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Arcutis Biotherapeutics
ARQT
$3.05B
| $162M | 13.84% |
+8,434,232
| New | +$143M |
|
|
2
Phathom Pharmaceuticals
PHAT
$759M
| $79.3M | 6.76% |
+5,827,415
| New | +$94.1M |
|
|
3
Mirum Pharmaceuticals
MIRM
$6.11B
| $78.5M | 6.69% |
+3,566,912
| New | +$72.8M |
|
|
SRRA
4
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $75.1M | 6.4% |
+2,342,198
| New | +$67.2M |
|
5
Krystal Biotech
KRYS
$10.4B
| $57.6M | 4.91% |
+866,250
| New | +$54.1M |
|
|
IMGO
6
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $57.3M | 4.88% |
+2,971,274
| New | +$61.6M |
|
7
Vaxcyte
PCVX
$9.05B
| $55.8M | 4.75% |
+2,309,554
| New | +$50.5M |
|
8
Syndax Pharmaceuticals
SNDX
$1.81B
| $55.5M | 4.73% |
+3,195,403
| New | +$53.8M |
|
|
KDNY
9
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $44.4M | 3.78% |
+2,712,041
| New | +$36.9M |
|
|
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $40.8M | 3.47% |
+2,421,563
| New | +$35.8M |
|
|
ALPN
11
DELISTED
Alpine Immune Sciences Inc
ALPN
| $37.5M | 3.2% |
+4,185,757
| New | +$36.2M |
|
12
Viridian Therapeutics
VRDN
$2.64B
| $32.2M | 2.74% |
+1,739,530
| New | +$33.4M |
|
|
CRNX
13
DELISTED
Crinetics Pharmaceuticals
CRNX
| $31.1M | 2.65% |
+1,414,823
| New | +$28.6M |
|
|
BCYC
14
Bicycle Therapeutics
BCYC
$296M
| $26.5M | 2.26% |
+603,521
| New | +$28.2M |
|
15
Tarsus Pharmaceuticals
TARS
$3.93B
| $23.8M | 2.03% |
+1,417,157
| New | +$26.3M |
|
|
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
| $23.2M | 1.98% |
+1,572,192
| New | +$22.6M |
|
17
AnaptysBio
ANAB
$1.69B
| $22.3M | 1.9% |
+899,700
| New | +$27.2M |
|
|
GRTS
18
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $21.6M | 1.84% |
+5,237,348
| New | +$27.7M |
|
19
Cogent Biosciences
COGT
$6.04B
| $19.9M | 1.69% |
+2,651,754
| New | +$18.5M |
|
20
Arvinas
ARVN
$601M
| $18.2M | 1.55% |
+270,331
| New | +$18.4M |
|
|
TCDA
21
DELISTED
Tricida, Inc. Common Stock
TCDA
| $17.1M | 1.46% |
+2,082,093
| New | +$18.8M |
|
|
SLN
22
Silence Therapeutics
SLN
$883M
| $16.7M | 1.43% |
+881,173
| New | +$17.6M |
|
|
MRUS
23
DELISTED
Merus
MRUS
| $16.6M | 1.42% |
+628,979
| New | +$16.9M |
|
|
AUTL
24
Autolus Therapeutics
AUTL
$580M
| $15.6M | 1.33% |
+3,746,857
| New | +$15.8M |
|
25
Passage Bio
PASG
$14.9M
| $15.5M | 1.32% |
+250,461
| New | +$20.6M |
|
Similar funds
AF
BWA
CCA
AT
SLG
TYCC
LP
CSP
Frazier Life Sciences Management's Q1 2022 Portfolio in Review
Q1 2022 is the first quarter with a 13F filing on record for Frazier Life Sciences Management, which disclosed 42 positions worth $1.17B. Its ten largest holdings account for 60% of the portfolio.
Its largest position is Arcutis Biotherapeutics: 8,434,232 shares worth $162M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, followed by Miscellaneous.
- Frazier Life Sciences Management's largest Q1 2022 buy was Arcutis Biotherapeutics: 8,434,232 shares worth $162M.
- Frazier Life Sciences Management's ten largest holdings make up 60% of its $1.17B portfolio in Q1 2022.
- Frazier Life Sciences Management disclosed 42 positions in Q1 2022, its first 13F filing on record.
Based on Frazier Life Sciences Management's 13F filing for Q1 2022, filed 16 May 2022.